Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
W. Marston Linehan, Peter A. Pinto, Ramaprasad Srinivasan, Maria Merino, Peter Choyke, Lynda Choyke, Jonathan Coleman, Jorge Toro, Gladys Glenn, Cathy Vocke, Bert Zbar, Laura S. Schmidt, Donald Bottaro, and Len Neckers .................................................................671s

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
William G. Kaelin, Jr...........................................................................................................................................680s

Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead
Jon Jones and Towia A. Libermann ..............................................................685s

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?
Allan J. Pantuck, Arie S. Belldegrun, and Robert A. Figlin ........................................................................693s

Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome
Christopher G. Wood ..................................................................................................................697s

Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
John S. Lam, Allan J. Pantuck, Arie S. Belldegrun, and Robert A. Figlin .............................................703s

Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
R. Houston Thompson, Haidong Dong, and Eugene D. Kwon .........................................................709s

Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
David F. McDermott ..................................................................................................................716s

Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Augusto C. Ochoa, Arnold H. Zea, Claudia Hernandez, and Paulo C. Rodriguez .....................721s

Reversal of Tumor-Mediated Immunosuppression
Johannes Vieweg, Zhen Su, Philipp Dahm, and Sergei Kusmartsev .................................................727s

Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang

Biologic Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
Brian I. Rini and W. Kimryn Rathmell ...........................................................................................741s

Sorafenib in Renal Cell Carcinoma
Keith T. Flaherty ......................................................................................................................747s

Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma
Daniel J. George ..........................................................................................................................753s
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Daniel Cho, Sabina Signoretti, Meredith Regan, James W. Mier, and Michael B. Atkins ..................................758s

Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer
Jeffrey A. Sosman, Igor Puzanov, and Michael B. Atkins ................................................................................764s

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma
Mark A. Rosen and Mitchell D. Schnall ............................................................................................................770s

Biomarkers for Monitoring Antiangiogenic Therapy
Rupal S. Bhatt, Pankaj Seth, and Vikas P. Sukhatme ........................................................................................777s
Clinical Cancer Research

13 (2)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/13/2 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |